Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation.

Qkine wins ‘Scale-up of the Year’ at the 2024 Cambridge Independent Business Awards

Qkine wins ‘Scale-up of the Year’ at the 2024 Cambridge Independent Business Awards

On the 26th September 2024, Qkine representatives Catherine Elton, CEO and Luana Ferrara, Head of R&D and Collaborations joined some of the most impressive Cambridge business leaders for an exciting evening of networking and entertainment at the Cambridge Independent Business awards ceremony held in the spectacular Great Hall at King’s College, Cambridge.

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform

Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management

CardiaTec Secures $6.5M Seed Funding to Advance Its Multi-omics Drug Discovery Platform for Cardiovascular Diseases

CardiaTec Secures $6.5M Seed Funding to Advance Its Multi-omics Drug Discovery Platform for Cardiovascular Diseases

CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has raised $6.5M in seed funding led by San Francisco-based Montage Ventures.

Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer

Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer

Qkine is delighted to announce the appointment of Rob Nixon to its leadership team as Commercial Director and Paul Grafham as Chief Financial Officer. With years of experience working with fast-growing biotechs and life science reagent suppliers, these appointments will support the execution of the company’s growth strategies and expansion of its commercial operations globally.

Abselion announces £1.1m project to develop next-gen cell platform for viral vector production

Abselion announces £1.1m project to develop next-gen cell platform for viral vector production

Biotechnology companies and research organisations in the UK and Canada are entering into a R&D project jointly funded by a 1.1 million GBP grant from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project is led by VVector Bio and joined by the NRC, Revvity and Abselion.


Interview with Rovco CEO: New technologies can close huge offshore wind skills gap

Interview with Rovco CEO: New technologies can close huge offshore wind skills gap

New technologies have the ability to massively close the huge skills gap and shortage of workers that is looming over the offshore wind industry, allowing 10 to 17 times more work to be done by one person, according to Brian Allen, CEO of Rovco, a UK company focused on automating offshore wind services by creating and deploying novel tech solutions.